Get started
Author

Frank-Ulrich Fricke

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
2019 · Michael F. Drummond, Peter J. Neumann, et al. · Value in Health · 92
Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation
2000 · K. Bestehorn, M. Biller, et al. · Medizinische Klinik - Intensivmedizin und Notfallmedizin · 63
Health Technology Assessment: A Perspective from Germany
2009 · Frank-Ulrich Fricke, Hans Peter Dauben · Value in Health · 32
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
2020 · Samuel Aballéa, Katia Thokagevistk, et al. · Journal of Market Access & Health Policy · 30
PDF
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe
2021 · Sean Tunis, Eve Hanna, et al. · Health Policy · 26
PDF
The implications of external price referencing on pharmaceutical list prices in Europe
2018 · Marcell Csanádi, Zoltán Kaló, et al. · Health Policy and Technology · 25
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study
2023 · Gérard de Pouvourville, David Cunningham, et al. · Value in Health · 17
PDF
The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
2022 · Michele A. Kohli, Michael Maschio, et al. · Vaccines · 17
PDF
Trends in decision-making process for pharmaceuticals in Western European countries
2001 · M.J.C. Nuijten, P. Berto, et al. · The European Journal of Health Economics · 14
Pharmabetriebslehre
2008 · Schöffski, Oliver, Fricke, Frank-Ulrich, et al. · Springer eBooks · 13
Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings
2021 · Zsuzsanna Ida Petykó, Zoltán Kaló, et al. · Cost Effectiveness and Resource Allocation · 12
PDF
Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmonize HTA
2022 · Lucia Gozzo, Kenneth Paterson, et al. · Frontiers in Drug Safety and Regulation · 11
PDF
3 Entscheidungsanalyse und Modellierungen
2011 · Uwe Siebert, Beate Jahn, et al. · Springer eBooks · 10
Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives
2021 · Zoltán Kaló, Zsuzsanna Ida Petykó, et al. · Cost Effectiveness and Resource Allocation · 9
PDF
[Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
2005 · Frank-Ulrich Fricke, Sigmund Silber · Herz · 5
Können Medikamente frei setzende Koronarstents eine Bypassoperation ersetzen?
2005 · Frank-Ulrich Fricke, Sigmund Silber · Herz · 5
Letter to the Editor
2005 · Frank-Ulrich Fricke · American Heart Journal · 4
Steuerungsinstrumente in der Arzneimittelversorgung
2008 · Frank-Ulrich Fricke · Springer eBooks · 3
Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark
2026 · Samuel Aballéa, Mondher Toumi, et al. · Journal of Market Access & Health Policy · 2
PDF
The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries
2020 · P. Newsome, J. Schattenberg, et al. · Digestive and Liver Disease · 2
Die pharmazeutische Industrie und der Arzneimittelmarkt
2008 · Frank-Ulrich Fricke, Oliver Schöffski · Springer eBooks · 2
Steuerungsinstrumente in der Arzneimittelversorgung
2002 · Frank-Ulrich Fricke · Springer eBooks · 2
The Future Market for Pharmaceutical Products in Germany
2000 · F.-U. Fricke, S. W�hling, et al. · The European Journal of Health Economics · 2
Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy
2026 · Elaine Julian, Nicolas S. H. Xander, et al. · Journal of Market Access & Health Policy · 1
PDF
Pgi27 the Burden of Non-alcoholic Steatohepatitis (nash) in the Eu5 Countries
2019 · C. Le Pen, F.U. Fricke, et al. · Value in Health · 1
PDF
Works count: 49
Citation count: 405
H-index: 11
I10-index: 13
Year
Topic
Type